Researchers implicate well-known protein in fibrosis

November 20, 2012

An international multi-disciplinary research team led by Northwestern Medicine scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.

This finding, recently reported in the , has implications for the treatment of scleroderma, a condition for which there currently is no effective treatment.

TLR4 was previously implicated in inflammation, but its role in was unknown. Fibrosis is a hallmark of scleroderma and contributes to a range of common diseases including , , and radiation-induced scarring.

"We found that when the gene for TLR4 was mutated in mice, the mice became resistant to experimental scleroderma," said the study's first author Swati Bhattacharyya, research assistant professor of rheumatology at Northwestern University Feinberg School of Medicine. "Moreover, scleroderma patients showed abnormal TLR4 levels in fibrotic skin and lung tissue. This tells us we have found a ."

Scleroderma is a which causes progressive tightening of the skin and can lead to serious internal organ damage and, in some cases, death. Scleroderma affects an estimated 300,000 people in the U.S., most frequently young-to-middle-aged women. Its cause and pathogenesis are unknown.

"The Northwestern research team continues to make fundamental discoveries that enhance our scientific understanding of scleroderma," said co-author John Varga, M.D., the John and Nancy Hughes Distinguished Professor of Rheumatology and professor of dermatology at Feinberg. "Careful dissection of the role of individual proteins in this disease enables us to make real progress toward novel treatments."

Researchers from Northwestern, Boston University, the University of Pittsburgh and the University Medical Center Nijmegen, Netherlands contributed to the study, which relied on tissue samples from human scleroderma patients and mouse models.

Agents that block TLR4 are already being developed for inflammation and sepsis in humans. Effective TLR4 inhibitor drugs may blunt and even possibly reverse the fibrosis in scleroderma, says Bhattacharyya. However, earlier attempts to develop therapeutics that block TLR4 have met with failure due to toxicity.

"These results, while significant, are preliminary. We now know that TLR4 plays a role in scleroderma, but much research remains to be done to develop safe and effective drugs to inhibit this pathway," she says.

The investigators are currently studying additional mouse models to better understand the role of TLR4 in fibrosis and are developing novel small molecules to selectively block TLR4 as a potential therapy.

Explore further: New genetic path for scleroderma: Patient biopsies reveal potential new target for therapy

Related Stories

New genetic path for scleroderma: Patient biopsies reveal potential new target for therapy

March 19, 2012
A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy. The finding, discovered by a cross-disciplinary team led ...

Cancer drug may also work for scleroderma

September 22, 2011
A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

Northwestern to explore personalized medicine for scleroderma

December 2, 2011
Northwestern Medicine researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study scleroderma, ...

Recommended for you

After a half-century of attempts, psilocybin has finally been synthesized in the lab

August 16, 2017
A team of researchers at Friedrich Schiller University Jena has figured how out to make psilocybin, the chemical responsible for creating hallucinations in people who consume the mushrooms that produce it naturally. In their ...

The unexpected role of a well-known gene in creating blood

August 16, 2017
One of the first organ systems to form and function in the embryo is the cardiovascular system: in fact, this developmental process starts so early that scientists still have many unresolved questions on the origin of the ...

Researchers unlock clues to how cells move through the body

August 16, 2017
During its 120-day cycle the circulatory system transports red blood cells and nutrients throughout the human body. This system helps keep the body in balance and fight against infections and diseases by filtering old or ...

Eating habits affect skin's protection against sun

August 15, 2017
Sunbathers may want to avoid midnight snacks before catching some rays.

The lining of our intestines uses an approach known to business to quickly process food

August 15, 2017
Every time we swallow food, cells that line the intestines must step up their activity in a sudden and dramatic manner. According to a new study by Weizmann Institute of Science researchers, reported in Science, they rise ...

Therapeutic fusion protein could mitigate blood vessel damage from cardiovascular disease

August 15, 2017
Scientists from Boston Children's Hospital Vascular Biology Program have revealed an engineered fusion protein that could recover blood vessel health following the onset of hypertension, atherosclerosis, stroke, heart attack, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.